Cover Image

PAPERBACK
$25.00



View/Hide Left Panel

4. Where are the gaps between what the public sector needs and what industry is already doing?

Gap Analysis and Discussion

1:30 RECONVENE

ELEMENT 2: A LEARNING CASE—THE CHILDREN'S VACCINE INITIATIVE

5. What have we learned? (NOTE: While particular topics are indicated for some individuals, all are highly knowledgeable about this activity and can speak to a range of relevant points.)

Panel Presentation and Discussion—Attempts to Modify the Structure of Incentives for Industry to Produce ''Social Products": The Illuminating Case of the Children's Vaccine Initiative

William Hausdorff (Wyeth-Lederle)

Pamela Johnson (United Nations)

Amie Batson (Vaccine Supply and Quality Unit, WHO Global Programme for Vaccines and Immunization)

William Muraskin (Department of History, Queens College)

Jack Melling (Salk Institute, Swiftwater)

Roy Widdus (WHO/Children's Vaccine Initiative)

Patents: Protection and Problems

Charles Caruso (Merck and Company, Inc.)

ELEMENT 3: OTHER MODELS AND MECHANISMS

Special Disease-Focused Initiatives:

Malaria Vaccine Development Board

Phillip Russell (Johns Hopkins School of Hygiene and Public Health)

International AIDS Vaccine Initiative (IAVI)

Seth Berkley (Rockefeller Foundation)

Legislative Mechanisms

Orphan Drug Act

Anne Marie Finley (Committee on Government Reform and Oversight, Subcommittee on Human Resources, U.S. House of Representatives)



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement